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 Abstract
Although the level and pace of population aging display high geographical variability, virtually all countries have been experiencing
growth in their elderly population, particularly in developed nations. Because aging is a major risk factor for atherosclerosis and associated
disease, it is of up most importance to unravel the molecular mechanisms involved in vascular aging. Telomeres are specialized DNA-protein
structures located at the ends of eukaryotic chromosomes whose length is progressively reduced in most somatic cells during aging. It is
accepted that telomere exhaustion contributes to organismal ageing at least by impairing cell proliferation and viability. An emerging
question is whether telomere erosion contributes to atherosclerosis. Here we discuss recent advances on the molecular control of telomere
length in vascular cells, as well as animal and human studies that address the role of telomeres in vascular pathobiology. Although the
interrelationships between telomere length and cardiovascular disease appear obvious, a chief question that remains unanswered is whether
telomere ablation is cause of vascular injury or a surrogate phenomenon.
D 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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Telomeres are specialized DNA-protein complexes
located at both ends of eukaryotic chromosomes. Func-
tional telomeres are required to prevent the recognition of
chromosomal ends as double-stranded DNA breaks, thus
preserving genome integrity and stability [1,2]. As
depicted in Fig. 1A, telomeric DNA consists of non-
coding double-stranded repeats of G-rich tandem sequen-
ces (TTAGGG in humans) that extend several thousand
base pairs and end in a 3V-overhang (G-strand overhang).
The synthesis of telomeric DNA requires the activity of
specialized telomere-associated proteins (i.e., telomerase,
TRAF1, TRAF2, Ku86, etc). The enzyme telomerase has a
catalytic telomerase reverse transcriptase (TERT) compo-0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publishe
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E-mail address: vandres@ibv.csic.es (V. Andre´s).nent and a telomerase RNA (Terc) that provides a template
for new telomeric DNA synthesis.
Telomere protection depends on several factors, includ-
ing the precise composition of telomere-associated pro-
teins, the level of telomerase activity, and telomere length
itself [1,2]. Cells with sufficiently long telomeres do not
require telomerase activity, but lack of telomerase activity
in cells with critically short telomeres leads to chromoso-
mal fusions, replicative senescence, and apoptosis (Fig.
1B). Telomerase expression and activity and telomere
length are regulated in a tissue-specific and developmental
manner in several species, including humans [3–6]. In
general, these parameters are greater during embryonic
development and become low or undetectable after birth,
although significant differences in adult tissues have been
reported. For instance, human telomeric DNA shortens at
an estimated rate of 29–60 base pairs per year (bp/year) in
liver, renal cortex and spleen, but telomere length is
maintained in cerebral cortex [7]. Notably, human prema-66 (2005) 213–221d by Elsevier B.V. All rights reserved.
Fig. 1. Telomere integrity and cellular homeostasis. (A) Left: Schematic showing telomeres (black circles) at both ends of chromosomes. Right: Enlargement of
the telomere showing the human telomeric DNA tandem repeat sequence, the telomeric RNA component (Terc), the catalytic telomerase reverse transcriptase
(TERT) subunit, and additional telomerase-associated proteins. (B) Telomere attrition occurs progressively in somatic cells with each mitotic cycle during
normal aging and passage in culture, due in part to low or absent telomerase activity. In contrast, high telomerase activity in germ and tumor cells allows the
maintenance of telomere integrity and an extended proliferative capacity. Accelerated telomere erosion is a characteristic of several human premature aging
syndromes (i.e., Werner syndrome, ataxia telangectasia, dyskeratosis congenita).
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 ture aging syndromes (i.e., Werner syndrome, ataxia
telangectasia, dyskeratosis congenita) are characterized by
an accelerated rate of telomere attrition (Fig. 1B).
Progressive telomere shortening in cell culture and during
aging of the whole organism is a characteristic of most
adult somatic cells, which exhibit low or absent telomerase
activity [8–10]. Of note in this regard, human TERT
(hTERT) is alternatively spliced in specific patterns by
different tissue types during development, and this
mechanism often leads to the expression of hTERT protein
lacking functional reverse transcriptase domains [11]. In
contrast to adult somatic cells, the extended proliferative
capacity of germ and tumor cells correlates with the
maintenance of high telomerase activity and long telo-
meres. The importance of telomere integrity for high rate
of cellular proliferation is further emphasized by TERT
gene transfer experiments, which result in reduced
replicative senescence and extended lifespan of numerous
cell types, including smooth muscle cells (SMCs) and
endothelial cells (ECs) (Table 1). By comparing the
chronological changes in the expression of cell cycle and
apoptosis-related genes in hTERT-transduced human nor-
mal fibroblasts and ECs, Kumazaki et al. [12] suggested
that cell-type specific differential gene expression aftertelomerase activation may be important to acquire telo-
mere-maintenance capacity and immortality.
Telomere length displays individual differences in both
rodents [5,6] and humans [7,13–15]. High variability of
telomeric DNA length in white blood cells (WBCs),
umbilical artery and skin from donor newborns independ-
ently of gender suggests that genetic and environmental
determinants that start exerting their effect during embry-
onic development are key determinants of telomere length
[13]. Further support to the notion that telomere size is
familial has arisen from human studies in twins [14,16]. By
measuring terminal restriction fragment (TRF) length in
WBC DNA taken from individuals from a family-based
cohort, Nawrot et al. [17] concluded that inheritance of
telomere length is linked to X chromosome.2. The importance of telomeres in vascular pathobiology
In the next sections, we will discuss tissue culture, animal
and human studies that highlight the importance of
telomeres in vascular pathobiology, with special emphasis
on recent insights into the mechanisms that alter telomere
homeostasis in response to several atherogenic stimuli and
Table 1
Cell culture studies implicating telomere length and telomerase in vascular
pathobiology
Cell type Main findings Refs.
Smooth
muscle
cell
(SMC)
Hypoxia-induced telomerase activation in
human SMCs correlates with increased
cellular proliferation
[55]
Telomerase activity correlates with
proliferation of primary SMCs, and its
inhibition attenuates hyperplastic growth
[56,81]
hTERT forced overexpression extends the
lifespan of rat SMCs
[80]
Endothelial
cell (EC)
Telomere attrition correlates with limited
proliferative capacity of passaged human
ECs
[60,82]
Telomerase ectopic overexpression or
inhibition affect the lifespan of human
aortic ECs
[58,83]
Constitutive hTERT expression enhances
the regenerative capacity of endothelial
progenitor cells
[54]
FGF-2, but not VEGF, upregulates
telomerase activity and delays the onset of
senescence in HUVECs
[51,52]
Estrogen activates the PI3K/Akt pathway in
human ECs, and Akt activation upregulates
human telomerase activity; in contrast,
PI3K inhibition and dominant negative Akt
mutant significantly reduce telomerase
activity in EC cultures
[29,31,32]
Estrogen induces nitric oxide production
and telomerase activity in vascular ECs.
[29,30]
Oxidized low density lipoproteins diminish
Akt and telomerase activity in ECs
[32]
Chronic oxidative stress compromises
telomere integrity and accelerates the onset
of senescence in human ECs
[35]
Antioxidants inhibit nuclear export of TERT
and delay replicative senescence of human
ECs
[39]
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 conditions (i.e., estrogens, oxidative stress, hypertension
and diabetes) (Table 1 and Fig. 1). Since collateral vessel
formation supports the restoration of blood flow into
ischemic territories and development of new vasa vasorum
enhances atherosclerosis [18,19], we will also discuss the
role of telomeres on neovascularization. The importance of
telomeres on cardiac pathobiology has been comprehen-
sively discussed elsewhere [20,21].
2.1. Telomeres and estrogens
Indirect effects on lipoprotein metabolism and direct
actions on vascular ECs and SMCs are thought to contribute
to the cardioprotective effects of estrogens in premeno-
pausal women [22–25]. It is noteworthy that human and
animal studies have shown higher telomerase activity and a
decelerated rate of age-dependent telomere exhaustion
resulting in greater telomere lengths in females than in
males [4,6,16,17,26,27]. These sex differences might be
directly related to estrogen-dependent activation of endo-thelial telomerase via phosphoinositol 3-kinase (PI3K)/Akt
and nitric oxide signaling. First, estrogen upregulates
hTERT mRNA, and this correlates with direct and indirect
effects on the hTERT promoter (specific binding of 17h-
estradiol to an imperfect palindromic estrogen-responsive
element, and 17h-estradiol-dependent induction of c-Myc/
Max binding to E-boxes, respectively) [28]. Second, nitric
oxide production may contribute to telomerase activation in
vascular ECs [29,30]. Third, treatment of human ECs with
estrogen activates the PI3K/Akt pathway [29], which in turn
leads to hTERT phosphorylation and activation [31]. In
contrast, either overexpression of dominant negative Akt or
PI3K inhibition attenuates telomerase activity in ECs, [32]
and Akt inactivation by proatherogenic oxidized low density
lipoproteins impairs telomerase activity in ECs [32].
Collectively, these studies suggest that a positive effect of
PI3K/Akt on telomerase expression and activity may
contribute to the maintenance of EC integrity and function.
Contrary to this notion, Miyauchi et al. [33] recently
reported that constitutive activation of Akt promotes
senescence-like arrest of human EC growth via a p53/p21-
dependent pathway. Additional studies are thus required to
clarify the links between telomere function, PI3K/Akt
signaling and EC pathobiology.
2.2. Telomeres and oxidative stress
Accumulation of oxidative damage is thought to play an
important role in aging and associated diseases [34].
Mounting evidence implicating oxidative stress in telomere
dysfunction includes the following: (1) Chronic oxidative
stress induces a rapid and sustained decrease in TERT
activity and accelerates telomere attrition in human umbil-
ical vein ECs (HUVECs) [35]; (2) maximum levels of
glutathione coincide with a peak of telomerase activity in
proliferating 3T3 fibroblasts; moreover, glutathione deple-
tion decreases by 60% telomerase activity, and restitution of
glutathione levels restores telomerase activity [36]; (3) age-
dependent telomere shortening in HUVECs is slowed down
by Asc2P, and oxidation-resistant derivative of vitamin C
which reduced by 53% the level of proatherogenic reactive
oxygen intermediates [37]; (4) oxidized low density lip-
oproteins inhibit EC telomerase activity [32]; (5) oxidative
stress induced in human ECs by exposure to H2O2 leads to
translocation of both endogenous and overexpressed hTERT
from the nucleus into the cytosol via Src kinase family-
dependent phosphorylation of hTERT tyrosine 707, which
reduces the antiapoptotic capacity of TERT; [38] further-
more, reduction of intracellular reactive oxygen species
formation by the antioxidant N-acetylcysteine prevented
mitochondrial damage and delayed nuclear export of TERT
protein, loss of TERT activity and the onset of replicative
senescence [39]; and (6) formation of 8-oxo-7,8-dhydro-2V-
deoxyguanosine at the GGG triplet in the telomeric DNA
sequence may be a mechanism facilitating telomere short-
ening induced by oxidative stress [40].
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 2.3. Role of telomeres in vascular pathobiology: lessons
learnt from cell culture and animal studies
The Terc-deficient mouse model has been a valuable
tool to investigate the impact of telomere ablation at the
organismal level [41–48]. The breeding of successive
generations of Terc-null mice is needed to reach critically
short telomeres that lead to abnormal chromosome end-to-
end fusions and symptoms of premature aging and disease,
such as infertility, graying of hair, alopecia, impaired
wound healing, small intestine and spleen atrophy, reduced
proliferation of T and B lymphocytes, and hematopoietic
disorders. Furthermore, late-generation Terc-null mice
display reduced lifespan. We will discuss in the next
sections studies with cultured cells, Terc-null mice,
spontaneously hypertensive rats and other animal models
that link telomeres and vascular pathobiology (Table 1 and
Fig. 2).
2.3.1. Atherosclerosis
Our recent studies using genetically modified mice
suggest that telomere shortening protects against athero-
scleoris [48]. We found that late-generation mice doubly
deficient for Terc and apolipoprotein E (Terc/apoE-KO)
have shorter telomeres and are protected from diet-induced
atherogenesis compared to atherosclerosis-prone apoE-null
counterparts with an intact Terc gene and longer telomeres,
in spite of comparable hypercholesterolemia. Telomere
exhaustion markedly inhibited the proliferative capacity of
cultured Terc/apoE-KO lymphocytes and macrophages
stimulated with several mitogens. Thus, telomere ablation
might attenuate atherogenesis by limiting leukocyte pro-
liferation. It remains to be established whether telomere
attrition affects additional events involved in atherogenesis,
such as the interaction between blood circulating leukocytes
and ECs, transendothelial migration of leukocytes, synthesisFig. 2. Telomeres and telomerase in atherosclerosis and hypertension. Human (
telomerase activity in atherosclerosis and hypertension are summarized. Succes
telomeres and associated diseases. Reference numbers are shown.of inflammatory mediators, and cellular proliferation,
migration, and apoptosis.
An important issue when interpreting the atheropro-
tective role of telomere exhaustion in hypercholesterole-
mic Terc/apoE-KO mice is that human aging is associated
with telomere erosion in most somatic cells [9,10], yet
atherosclerosis is more prevalent within the elderly. These
seemingly conflicting findings might be reconciled
accepting that accumulation of cellular damage imposed
by prolonged exposure to cardiovascular risk factors may
ultimately prevail over protective mechanisms such as
telomere shortening. The evidence linking telomere length
and human atherosclerosis is discussed below (see
Section 2.4.1).
2.3.2. Neovascularization
Proliferation of vasa vasorum promotes atherosclerosis
[18]. On the other hand, therapeutic neovascularization is
essential for the restoration of blood flow into ischemic
territories in the adult organism, which depends on the
development of new collateral vessels from established
vascular networks (angiogenesis) and on de novo vessel
formation by endothelial progenitor cells (vasculogenesis)
[19]. Using an experimental model of limb ischemia, Rivard
et al. [49] demonstrated an impairment of angiogenesis in
old vs. young rabbits. They also showed age-dependent
diminished expression of the angiogenic cytokine vascular
endothelial growth factor (VEGF), and old rabbits exposed
to exogenous VEGF exhibited a similar increase in blood
pressure ratio, angiographic score, and capillary density than
did young counterparts. Thus, VEGF downregulation might
be critical for age-dependent impairment of angiogenesis in
response to ischemia, and this may result from reduced
activity of the transcription factor hypoxia-inducible 1 (HIF-
1) [50]. Remarkably, whereas both angiogenic cytokines
VEGF and fibroblast growth factor-2 (FGF-2) elicited aleft) and animal (right) studies that have implicated telomere length and
sive generations of Terc-null mice are necessary to reach critically short
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 mitogenic response in cultured HUVECs, only FGF-2
induced the upregulation of hTERT mRNA and enzymatic
activity and delayed the appearance of a senescent
phenotype [51,52]. Because of these differences, it would
be interesting to compare in old rabbits the angiogenic
response elicited by exogenous FGF-2 and VEGF.
Overexpression of hTERT in human dermal micro-
vascular ECs (HDMECs) augments their capacity to form
more durable microvascular structures when subcutaneously
xenografted in severe combined immunodeficiency mice
[53]. Similarly, hTERT gene transfer into human endothelial
progenitor cells improves their proliferative and migratory
activity, enhances survival, and augments neovasculariza-
tion when applied in a murine hindlimb ischemia model
[54].
Recruitment of SMCs and pericytes into new capillaries
composed by a monolayer of ECs is important for their
stabilization and maturation into fully functional vessels.
Hypoxia is a major angiogenic stimulus that induces TERT
protein expression and phosphorylation in cultured SMCs
[55]. Telomerase inhibition shortened the life span of
hypoxic cultures, and constitutive TERT expression
extended life span under normoxia, suggesting that hypo-
xia-mediated telomerase activation promotes long-term
SMC growth. It remains to be established if chronic hypoxia
can induce endothelial telomerase activity.
Telomere exhaustion in late generation Terc-null mice
leads to a sharp decrease in angiogenesis in both Matrigel
implants and murine melanoma grafts, diminished tumor
cell proliferation, increased tumor cell apoptosis, and a
lower tumor growth rate [45]. Given the data implicating
neointimal angiogenesis as a mechanism contributing to
atheroma growth [18], it will be instructive to compare
neointimal vasa vasorum density in late-generation Terc/
apoE-KO mice with short telomeres and apoE-null counter-
parts with intact telomeres.
2.3.3. Hypertension
In the aorta of spontaneously hypertensive rats, but not
in other tissues, telomerase is activated before the onset of
hypertension, and telomeres are lengthened both in vivo
and in cultured SMCs from these animals [56]. Down-
regulation of telomerase by TERT antisense RNA delivery
arrested the increased proliferation of spontaneously hyper-
tensive rat vascular SMCs and induced apoptosis by a
mechanism that can be reversed by p53 overexpression and
worsened by lowering p53. It was concluded that selective
TERT activation and subsequent telomere lengthening in
aortic medial SMCs are the driving force for the imbalance
between cell proliferation and apoptosis that ultimately
results in the vascular remodeling seen in genetic hyper-
tension. Hamet et al. [57] observed in the kidney of
spontaneously hypertensive rats a transient hyperplasic
response during the first 2 weeks of postnatal life that
was absent in age-matched normotensive controls. Because
shorter telomeres are detected in the kidney of sponta-neously hypertensive rats at all ages examined, the authors
suggested that kidney cells from these animals are
subjected to increased turnover, potentially leading to their
accelerated aging.
2.4. Role of telomeres in vascular pathobiology: evidence
from human studies
2.4.1. Atherosclerosis
By inducing replicative senescence, age-dependent
telomere erosion may contribute to progressive endothelial
dysfunction and atherosclerosis. Indeed, a characteristic
senescent phenotype is observed in the endothelium of
atherosclerotic lesions [58]. Of note, overexpression of a
dominant-negative mutant of telomere repeat binding
factor 2 (TRF2) induces senescence in human aortic EC
cultures, and TERT transduction can prevent replicative
senescence of these cells [58]. Both telomere shortening
and increased frequency of aneuploidy is observed in ECs
from the aged abdominal aorta [59]. Remarkably, telomeric
DNA shortening occurs at a greater rate in the endothelium
of iliac arteries vs. iliac veins (102 vs. 47 bp/year,
respectively), and age-dependent intimal telomere attrition
is greater in the iliac artery compared to the internal
thoracic artery (147 vs. 87 bp/year, respectively), [60] a
vessel subjected to a reduced amount of hemodynamic
stress. Okuda et al. [61] also reported increased age-
dependent telomere ablation in both the intima and media
of the distal vs. proximal abdominal aorta, and they found
an inverse correlation between atherosclerotic grade and
telomere length (although this relationship was not statisti-
cally significant after adjustment for age). Taken together,
these studies suggest a higher rate of telomere shortening
in aged vascular beds with increased shear wall stress and
enhanced cellular turnover.
Circulating leukocytes are key players during athero-
sclerosis [62–65]. Recent studies have compared telomere
length in WBCs from healthy controls and cardiovascular
patients. Patients with vascular dementia, a disorder that is
frequently associated with cerebrovascular atherosclerosis
and stroke, have significantly shorter telomeres in WBCs
compared with three age-matched control groups, namely
cognitively competent patients suffering from cerebrovas-
cular or cardiovascular disease alone, patients with
probable Alzheimer’s dementia, and apparently healthy
control subjects [66]. Likewise, leukocyte average telo-
mere length in 10 patients suffering severe coronary artery
disease (CAD) was significantly reduced compared with
20 controls with normal coronary angiograms after
adjustment for age and sex [67]. In a larger study
including 180 controls and 203 cases of premature
myocardial infarction (MI), age-and sex-adjusted mean
TRF length of controls was significantly larger than that
of patients, and subjects with shorter than average
telomeres had between 2.8- and 3.2-fold higher risk of
MI [68]. Furthermore, analysis of telomere length in
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 blood DNA from 143 normal unrelated individuals over
60 years of age disclosed an association between shorter
telomeres and poorer survival that was partly attributed to
a 3.18-fold mortality rate from heart disease and a 8.54-
fold higher mortality rate from infectious disease [69].
Taken together, these human studies establish a link
between telomere shortening in WBCs and cardiovascular
disease. Whether telomere ablation in these scenarios is a
surrogate phenomenon or a mediator or injury remains to
be established (see Section 4).
2.4.2. Hypertension and diabetes
Hypertensive patients are more prone to atherosclerotic
lesions and acute ischemic events than normotensive
individuals [70]. Analysis of 49 twin pairs (38 males
and 60 females between the age of 18 and 44 years)
revealed a positive correlation between WBC TRF and
diastolic blood pressure [16]. Because TRF length and
systolic blood pressure were inversely associated, telomere
length seems to negatively correlate with pulse pressure.
Notably, the link between TRF length and pulse pressure
was independent of gender, and both parameters appeared
highly heritable. Benetos et al. [27] also investigated
WBC telomere length and blood pressure parameters that
are associated with stiffness of large arteries (pulse
pressure and pulse wave velocity) in individuals who
were not under antihypertensive medications (120 men, 73
women, mean age of 56F11 years). While telomere
length negatively correlated with age in both sexes,
multivariate analysis showed that telomere shortening
significantly contributes to increased pulse pressure and
pulse wave velocity only in men. In both studies, women
showed age-adjusted longer telomeres, suggesting that
biological aging is slowed down in women. More
recently, Benetos et al. [71] examined the relationship
between WBC telomere length and carotid artery athero-
sclerosis in 163 treated hypertensive men who were
volunteers for a free medical examination. They found
that telomere length was shorter in hypertensive men with
carotid artery plaques vs. hypertensive men without
plaques (8.17F0.07 vs. 8.46F0.07 kb; pb0.01), and
multivariate analysis revealed that, in addition to age,
telomere length significantly predicts the presence of
carotid artery atherosclerosis.
The prevalence of both microvascular and macrovascular
disease is significantly increased in diabetic patients [72].
Telomere length in WBCs from insulin-dependent diabetes
mellitus patients is reduced compared with age-matched
nondiabetic subjects [73]. This parameter was similar in non
insulin-dependent diabetes mellitus patients and nondiabetic
controls, suggesting that telomere erosion only occurs in a
subset of WBCs that participate in the pathogenesis of
insulin-dependent diabetes mellitus. Further support impli-
cating telomere exhaustion as a mechanism contributing to
coronary atherosclerosis under some circumstances of
metabolic disorders arises from the observation that hyper-cholesterolemic and diabetic CAD patients display shorter
telomeres in peripheral blood mononuclear cells than healthy
controls [74].
2.4.3. Neovascularization
The importance of telomerase in human angiogenesis is
highlighted by the progressive induction of hTERT mRNA
expression in human ECs of newly formed vessels within
tumors [75]. Endothelial hTERT expression was observed in
29%, 56% and 100% of low-grade astrocytomas, anaplastic
astrocytomas and advanced glioblastomas multiforme,
respectively. While the proliferation rate and hTERT mRNA
expression are dissociated in human ECs from low-grade
and anaplastic astrocytomas, high proliferation rate and
hTERT mRNA level positively correlated in glioblastomas
multiforme. Remarkably, hTERT mRNA and protein
expression and telomerase activity are induced in EC
cultures exposed to diffusible factor(s) produced by human
glioblastoma cells [76].3. Telomerase gene transfer for therapeutic
revascularization
By analyzing the offspring obtained by mating hetero-
zygous Terc+/ mice and late-generation Terc-null mice,
which have short telomeres, unstable chromosomes and
signs of premature aging, Samper et al. [77] demonstrated
that critically short telomeres can become fully functional
by restoration of telomerase. Because age-dependent
telomere erosion may compromise the reestablishment of
adequate blood supply into ischemic territories by limiting
de novo vessel formation (see Section 2.3.2), telomerase
gene transfer appears an attractive strategy to boost
therapeutic neovascularization. It has been shown that ex
vivo expanded human endothelial progenitor cells enhance
therapeutic neovascularization in animals, [78] and in vivo
transplantation of hTERT-transduced endothelial progeni-
tors increased capillary density and limb salvage in a murine
model of hindlimb ischemia [54]. Nonetheless, telomere-
independent barriers might limit the transplantation poten-
tial of murine hematopoietic stem cells, since TERT
overexpression in these cells did not extend transplantation
capacity in spite of preventing telomere loss during serial
transplantation [79].
McKee et al. [80] have provided evidence that hTERT
transduction may be an appropriate strategy for the
production of tissue-engineered human arteries for bypass
surgery. Compared with control cells, passaged human
aortic SMCs overexpressing hTERT maintained telomere
length, disclosed extended lifespan, and retained a normal
morphology and a differentiated, non-malignant phenotype
at late-passage. Remarkably, engineered vessels containing
HUVECs and hTERT-transduced SMCs showed improved
cellular viability and were mechanically and architecturally
superior to vessels generated from non-transduced SMCs.
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 4. Concluding remarks
By imposing chromosome abnormalities, replicative
senescence, and apoptosis, progressive telomere shortening
in somatic cells is thought to contribute to aging and
associated disorders. Both animal and human studies suggest
that the maintenance of telomere integrity is essential for
effective neovascularization, and btelomerizationQ of endo-
thelial progenitors by means of hTERT gene transfer may be
an efficient strategy to boost therapeutic neovascularization
of ischemic tissues after acute infarction. Regarding the role
of telomeres in atherosclerosis, it has been shown that
telomeres are shorter in human arterial tissue from athero-
sclerosis-prone vs. atherosclerosis-resistant vascular beds, as
well as in WBCs from hypertensive, diabetic and CAD
patients compared to unaffected controls. Thus, telomere
exhaustion may be a primary abnormality that renders the
organism more susceptible to atherogenic stimuli. Challeng-
ing this notion, atherosclerosis induced by dietary cholesterol
is significantly reduced in Terc/apoE-KO mice with critically
short telomeres compared to apoE-null counterparts with
intact telomeres, in spite of comparable hypercholesterole-
mia. These seemingly contradictory findings may reflect
profound differences in telomere pathobiology between
humans and mice. Alternatively, because SMC and leukocyte
proliferation is a characteristic of atherosclerosis and
telomere shortening is greater in highly proliferative cells,
reduced telomere length in human atherosclerotic tissue and
WBCs from hypertensive, diabetic and CAD patients may be
a surrogate phenomenon. Thus, establishing conclusively
whether telomere ablation is cause or consequence of
vascular injury will require prospective epidemiological
studies to assess if newborns with shorter telomeres are more
prone to cardiovascular disease in adulthood independently
of known cardiovascular risk factors. Of note in this regard, a
high degree of individual variability is observed in human
telomere length, which seems to be controlled by both genetic
and environmental factors. In addition to epidemiological
studies, further basic research is needed to assess whether
genetic and environmental cardiovascular risk factors affect
telomerase activity and/or telomere length, and to gain
mechanistic insight into the role of telomerase and additional
telomere-associated proteins in cardiovascular pathobiology.Acknowledgements
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